Sellas Life Sciences Group Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sellas Life Sciences Group Inc 's ROA in the second quarter of 2026?
Sellas Life Sciences Group Inc recorded a cumulative net loss of $-32 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -33.29%.

However, within the Healthcare sector 443 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3825, from total ROA ranking in the first quarter of 2026 at 4635.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	351.91 %	226.63 %	303.18 %	94.51 %	113.67 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-32	-29	-27	-26	-26
Return On Assets (TTM)	-33.29 %	-42.63 %	-54.5 %	-75.06 %	-92.79 %
SLS's Total Ranking	# 3825	# 4635	# 4239	# 4416	# 4574
Total Assets (TTM) in million	146	114	78	52	32
Seq. Total Assets Change	27.86 %	45.74 %	51.96 %	59.59 %	-7.58 %
Seq. Net Income Change	-	-	-	-	-

SLS's 5 Years Annual ROA >> Back to SLS Management Effectiveness >> Compare SLS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 170
Sector	# 444
Overall	# 3660

Return On Assets Statistics
High	Average	Low
-11.5 %	-97.78 %	-255.78 %
(Mar 31 2014)		(Jun 30 2024)

News about Sellas Life Sciences Group Inc Return on Assets ROA

Evaluating the Implications of Rare Pediatric Disease Designation for Galinpepimut-S in Pediatric Acute Myeloid Leuke...

Recent announcements from SELLAS Life Sciences Group Inc. have spotlighted its asset, Galinpepimut-S (GPS), which has received the U.S. FDA s Rare Pediatric Disease Designation (RPDD) for treating pediatric acute myeloid leukemia (AML). As GPS continues its clinical journey, notably through the ongoing Phase 3 REGAL trial in adult AML patients, the company faces significant financial pressures, culminating in a substantial net loss for the recent fiscal year. FDA s Rare Pediatric Disease Designation The U.S. FDA s Rare Pediatric Disease Designation is an important milestone that highlights the therapeutic potential of GPS in a pressing healthcare scenario pediatric AML, a rare and aggressive form of cancer. The designation can expedite the drug’s development and review process, potentially enhancing accessibility to a treatment desperately needed for this vulnerable population. This designation also positions GPS favorably within the competitive pharmaceutical landscape, as therapies targeting rare diseases are often prioritized, leading to quicker approvals and market entry.

Sellas Life Sciences Group Focuses on Clinical Advancements Amid Executive Leadership Reorganization

Sellas Life Sciences Group, a renowned late-stage clinical biopharmaceutical company dedicated to developing innovative therapies for a wide range of cancer indications, has recently announced a strategic reorganization of its executive leadership. With an aim to enhance its clinical programs and optimize resource allocation, the company has streamlined its management team, resulting in the departure of Senior Vice President and Chief Commercial Officer, Robert Francomano, as well as Executive Vice President, General Counsel, and Corporate Secretary, Barbara Wood.
This strategic move by Sellas Life Sciences Group reflects the company s commitment to prioritizing the advancement of its critical clinical programs. By focusing on its core expertise and clinical capabilities, the company aims to strengthen its position in the highly competitive field of oncology research and development.

Financial Statements
Sellas Life Sciences Group Inc 's Assets	$ 146 million	SLS's Balance sheet
Sellas Life Sciences Group Inc 's Income	$ -10 million	Quarterly SLS's Income Statement
SLS's Income by Division		See SLS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	303.18 %	212.46 %	-70.31 %	-20.29 %	-42.94 %
Total Assets in million	78	19	6	21	26
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-27	-31	-37	-41	-21
Annual Return On Assets	-34.29 %	-158.92 %	-600.42 %	-197.21 %	-78.78 %

SLS's 5 Years Annual ROA >> Back to SLS Management Effectiveness >> Compare SLS ROA to its Competitors

More Return On Assets Ratios
SLS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SLS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SLS's Competitors
Subscribers only: Roa for Sellas Life Sciences Group Inc 's Suppliers
Subscribers only: Return On Assets for SLS's Customers

You may also want to know
SLS's Roi	SLS's Inventory Turnover Ratio	SLS's Growth Rates	SLS's Dividend Comparisons
	SLS's Profitability Ratios	SLS's Asset Turnover Ratio	SLS's Dividend Growth
SLS's Roe	SLS's Valuation Ratios	SLS's Financial Strength Ratios	SLS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T22:17:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.